appear
spread
highli
pathogen
avian
influenza
hpai
rais
concern
possibl
pandem
current
prevent
measur
includ
develop
prepandem
influenza
vaccin
stockpil
neuraminidas
inhibitor
howev
benefit
significantli
reduc
mutat
hemagglutinin
neuraminidas
result
antigen
chang
appear
drugresist
respect
drug
target
innat
immun
system
achiev
heighten
antivir
state
repres
anoth
class
antivir
agent
could
contribut
control
treatment
influenza
infect
studi
pika
stabil
dsrna
provid
broadspectrum
prophylaxi
number
influenza
virus
addit
pika
admix
influenza
vaccin
prepar
includ
formalininactiv
wholevirion
vaccin
signific
adjuv
effect
lead
acceler
viral
clearanc
observ
murin
model
biolog
effect
appear
mediat
abil
pika
promot
matur
dendrit
cell
includ
upregul
costimulatori
molecul
induct
variou
cytokin
chemokin
tolllik
receptor
shown
recogn
pika
concentrationdepend
manner
potenc
versatil
activ
make
pika
attract
candid
use
influenza
pandem
effect
tool
control
influenza
pandem
suitabl
vaccin
optim
effect
pandem
vaccin
need
base
caus
strain
therefor
vaccin
produc
pandem
strain
identifi
criterion
pose
seriou
constraint
capabl
vaccin
manufactur
prepar
pandem
vaccin
advanc
stockpil
addit
number
studi
shown
hemagglutinin
ha
molecul
avian
virus
poorli
immunogen
g
antigen
time
normal
dose
human
influenza
viru
ha
requir
elicit
potenti
protect
respons
substanti
number
subject
need
larger
antigen
dose
reduc
avail
limit
pandem
vaccin
attempt
increas
immunogen
antigen
adjuv
like
alum
incorpor
vaccin
formul
although
alum
may
enhanc
magnitud
antibodi
respons
high
dose
antigen
signific
antigenspar
effect
adjuv
proprietari
oil
emuls
adjuv
test
data
indic
inclus
adjuv
vaccin
prepar
would
significantli
increas
antibodi
titer
given
likelihood
suitabl
vaccin
avail
onset
pandem
initi
protect
pandem
may
reli
antivir
treatment
prophylaxi
current
avail
antiinfluenza
drug
includ
neuraminidas
inhibitor
oseltamivir
zanamivir
ionchannel
blocker
adamantan
success
drug
prophylaxi
therapeut
base
suscept
virus
drug
recent
report
studi
howev
shown
number
isol
resist
drug
drug
class
drug
alon
may
thu
insuffici
protect
human
popul
influenza
pandem
altern
antigenindepend
approach
could
slow
transmiss
viru
provid
time
vaccin
product
thu
highli
desir
tolllik
receptor
tlr
collect
receptor
detect
conserv
molecular
compon
encod
microorgan
review
ref
stimul
receptor
specif
ligand
lead
activ
innat
immun
cell
dendrit
cell
dc
macrophag
nk
cell
varieti
signal
pathway
nfb
transcript
factor
cjun
termin
kinas
jnk
mitogenactiv
protein
kinas
mapk
result
quantit
qualit
chang
immunolog
function
includ
antigen
present
addit
cytokin
produc
vivo
shortli
tlr
activ
product
cytokin
result
antivir
effect
observ
number
infect
model
exampl
administr
synthet
lipid
analog
agonist
protect
mice
influenza
challeng
possibl
explan
antiinfluenza
effect
could
relat
product
type
interferon
induc
activ
ifnstimul
gene
includ
mx
protein
protein
kinas
r
oligoadenyl
synthetas
induct
protein
increas
resist
replic
influenza
viru
present
studi
design
investig
efficaci
pika
synthet
stabil
form
doubl
strand
rna
standalon
agent
antivir
effect
evalu
efficaci
pika
adjuv
coadminist
inactiv
influenza
vaccin
includ
vaccin
result
show
pika
potent
antiinfluenza
effect
administ
h
prior
immedi
influenza
viru
challeng
mice
antivir
effect
strainspecif
use
immunoadjuv
pika
abl
achiev
signific
antigenspar
effect
incub
immatur
dc
pika
alter
express
pattern
number
immun
gene
addit
pika
capabl
interact
human
mous
lead
product
nfb
thu
face
potenti
influenza
pandem
pika
could
candid
prophylact
drug
could
use
adjuv
increas
popul
coverag
pandem
vaccin
becom
avail
specif
pathogenfre
spf
male
balbc
mice
week
old
purchas
centr
anim
resourc
care
nation
univers
singapor
anim
protocol
use
studi
review
approv
institut
anim
care
use
committe
iacuc
dso
nation
laboratori
singapor
apuerto
reassort
viru
bear
ha
neuraminidas
na
gift
professor
lorena
brown
univers
melbourn
american
type
cultur
collect
atcc
reverseengin
influenza
viru
made
base
method
describ
hoffmann
et
al
use
express
plasmid
provid
dr
brendon
hanson
dso
nation
laboratori
singapor
ha
sequenc
clade
subclad
viru
close
relat
download
genbank
synthes
geneart
ag
regensburg
germani
virus
grown
allanto
caviti
embryon
chicken
egg
day
c
allanto
fluid
pool
divid
aliquot
store
c
use
south
hemispher
season
influenza
vaccin
fluvax
csl
ptd
ltd
victoria
australia
virion
reverseengin
viru
concentr
ultracentrifug
resuspend
pb
formalininactiv
purifi
wholevirion
vaccin
prepar
inactiv
virion
formalin
day
c
follow
dialysi
pb
total
protein
concentr
vaccin
measur
coomassi
plu
pierc
biotechnolog
inc
il
usa
amount
ha
content
estim
total
protein
content
complet
incomplet
freund
adjuv
cfa
ifa
obtain
sigmaaldrich
st
loui
usa
pika
obtain
newbiom
pika
pte
ltd
singapor
intranas
immun
group
mice
anesthet
intraperiton
ip
inject
ketamin
xylaxin
follow
administr
immunogen
l
immun
subcutan
sc
rout
immunogen
administ
l
base
tail
select
experi
g
pika
given
anesthet
mice
volum
l
given
sc
ip
rout
g
pika
given
l
volum
per
dose
pika
contain
dsrna
greater
base
pair
length
three
week
final
vaccin
mice
challeng
pfu
variou
strain
influenza
viru
volum
l
mice
sacrif
variou
timepoint
pulmonari
viral
titer
determin
use
previous
describ
method
mice
anesthet
ketaminexylaxin
inject
blood
sampl
collect
orbit
plexu
sera
collect
store
c
analysi
titer
immunogenspecif
antibodi
quantifi
elisa
previous
describ
avid
elisa
carri
use
previous
describ
method
cell
maintain
optimem
invitrogen
fetal
calf
serum
transfect
flatbottom
plate
previous
describ
sampl
test
triplic
six
hour
stimul
luciferas
activ
sampl
measur
commerci
kit
promega
corpor
wi
usa
rel
stimul
nfb
calcul
normal
luciferas
activ
activ
express
use
read
unstimul
well
baselin
level
express
variou
cytokin
gene
determin
use
lightcycl
roch
usa
use
primer
describ
giulietti
et
al
sampl
contain
g
total
rna
abovement
dc
experi
use
microarray
analysi
piqor
immunolog
microarray
miltenyi
biotech
gladbach
germani
use
sampl
amplifi
label
differ
fluorochrom
accord
manufactur
instruct
sampl
pikastimul
dc
unstimul
dc
label
respect
hybrid
slide
scan
use
imagen
softwar
biodiscoveri
gene
print
quadrupl
array
net
signal
intens
data
normal
calcul
ratio
perform
miltenyi
biotech
use
piqor
analyz
softwar
one
million
cell
stimul
g
pika
g
lp
sigmaaldrich
overnight
supernat
collect
cytokin
protein
level
measur
use
bioplex
protein
array
system
biorad
hercul
ca
duplic
standard
curv
accord
manufactur
instruct
signific
differ
two
differ
group
assess
mannwhitney
test
use
prism
graphpad
softwar
ca
usa
report
p
valu
consid
significantli
differ
studi
murin
influenza
model
employ
demonstr
antivir
properti
pika
model
anesthet
mice
challeng
influenza
viru
mimic
total
respiratori
tract
infect
pulmonari
viral
titer
reach
peak
day
postinfect
pi
remain
high
level
till
day
pi
data
shown
use
model
group
five
mice
given
g
pika
h
prior
challeng
plaqu
form
unit
pfu
pulmonari
viral
titer
lung
determin
day
pi
shown
fig
mice
receiv
pika
treatment
h
pi
lowest
pulmonari
viral
titer
day
significantli
lower
titer
control
mice
receiv
pb
p
addit
signific
reduct
pulmonari
viral
titer
also
observ
mice
receiv
one
dose
pika
h
prior
infect
differ
pulmonari
viral
titer
group
receiv
daili
treatment
group
receiv
one
dose
pika
statist
signific
p
demonstr
pika
inhibitori
effect
influenza
viral
replic
vivo
interest
determin
optim
condit
treatment
examin
mice
given
differ
concentr
pika
challeng
pfu
viru
mice
treat
h
sacrif
day
dosedepend
respons
observ
fig
mice
given
g
pika
daili
lowest
mean
viral
titer
among
group
inhibitori
effect
pika
viral
replic
detect
g
per
dose
g
per
dose
p
determin
whether
pika
could
use
treatment
option
time
infect
mice
given
pika
immedi
infect
pfu
viru
shown
fig
treatment
protocol
effect
reduc
pulmonari
viral
titer
titer
significantli
differ
prophylaxi
group
receiv
pika
h
prior
infect
p
howev
appar
daili
treatment
prefer
group
receiv
singl
dose
significantli
higher
titer
viru
lung
compar
receiv
daili
dose
p
intranas
administr
pika
produc
signific
antiinfluenza
effect
compar
sc
ip
administr
drug
fig
though
pulmonari
viral
titer
treat
mice
still
significantli
lower
titer
pb
control
group
p
demonstr
effect
pika
inhibit
replic
viru
vivo
sought
determin
whether
similar
inhibit
would
observ
differ
influenza
virus
group
five
mice
given
pika
treatment
challeng
pfu
previous
describ
day
pi
viral
titer
pikatr
group
significantli
lower
titer
pb
group
regardless
subtyp
challeng
virus
fig
c
p
respect
addit
mice
also
challeng
higher
dose
viru
pfu
ld
respect
shown
fig
b
pikatr
mice
lower
pulmonari
titer
pb
control
group
higher
challeng
dose
p
addit
challeng
pfu
mem
reduct
viral
titer
pikatr
mice
compar
pb
control
group
fig
demonstr
therapeut
potenti
treatment
group
five
mice
challeng
pfu
receiv
pika
treatment
h
pi
day
pi
shown
fig
signific
reduct
pulmonari
viral
titer
observ
pikatr
mice
p
compar
pbstreat
group
therefor
summari
demonstr
pika
abil
inhibit
replic
sever
strain
influenza
vivo
although
intranas
administr
drug
establish
infect
provid
best
protect
substanti
viral
reduct
could
still
achiev
drug
given
cours
establish
infect
sinc
pika
effect
adjuv
hepat
b
vaccin
examin
whether
pika
could
enhanc
immunogen
influenza
vaccin
sought
demonstr
enhanc
humor
respons
would
lead
signific
viral
reduct
replic
challeng
viru
previou
studi
show
administr
g
per
dose
differ
form
influenza
vaccin
could
induc
robust
antibodi
respons
without
extern
adjuv
protect
viral
challeng
shown
fig
mice
immun
singl
dose
trival
vaccin
g
sc
robust
antibodi
respons
compar
induc
vaccin
admix
cfa
vaccin
dose
reduc
fold
g
reduct
magnitud
antibodi
respons
mimic
vaccin
shortag
situat
dose
g
reduct
optim
dose
select
evalu
whether
inclus
pika
could
compens
reduct
antigen
concentr
group
five
mice
vaccin
suboptim
dose
fluvax
vaccin
sc
rout
three
week
prime
sera
collect
mice
boost
sera
collect
mice
week
boost
shown
fig
pika
act
potent
adjuv
enhanc
immunogen
season
influenza
vaccin
group
four
mice
vaccin
either
l
fluvax
influenza
vaccin
contain
g
ha
subtyp
pb
cfa
subcutan
rout
day
sera
collect
antibodi
titer
sera
determin
elisa
assay
use
fluvax
coat
antigen
b
group
five
mice
vaccin
l
fluvax
influenza
vaccin
contain
ng
ha
subtyp
pb
either
subcutan
rout
base
tail
intranas
rout
group
receiv
vaccin
addit
adjuv
indic
xaxi
receiv
pika
adjuv
g
pika
admix
vaccin
prior
administr
day
postvaccin
sera
collect
mice
receiv
anoth
boost
rout
sera
collect
day
antibodi
titer
sera
determin
elisa
assay
use
fluvax
coat
antigen
dot
repres
antibodi
titer
individu
mous
primari
secondari
antibodi
titer
repres
black
red
dot
respect
line
repres
geometr
mean
antibodi
titer
group
symbol
indic
differ
two
group
statist
signific
p
c
determin
level
protect
mediat
antibodi
respons
mice
challeng
pfu
intranas
week
boost
pulmonari
viral
titer
determin
day
postinfect
close
circl
repres
lung
viru
titer
individu
mous
line
repres
geometr
mean
titer
group
mice
percent
reduct
mean
viral
titer
rel
pb
control
group
shown
column
data
symbol
indic
differ
two
group
statist
signific
p
serum
sampl
dilut
avid
antibodi
test
ureadisplac
elisa
od
ureatr
plate
express
percent
untreat
plate
data
repres
mean
standard
deriv
five
mice
fig
two
five
mice
receiv
vaccin
without
adjuv
sc
rout
detect
amount
antiha
antibodi
primari
respons
cfa
group
four
mice
antiha
antibodi
wherea
anim
vaccin
pika
group
detect
level
antiha
antibodi
secondari
respons
although
mice
given
vaccin
alon
develop
antiha
antibodi
antibodi
titer
significantli
lower
given
vaccin
pika
p
intranas
deliveri
vaccin
none
vaccin
protocol
abl
elicit
detect
antiha
respons
one
dose
two
dose
vaccin
given
pika
vaccin
recipi
group
show
low
titer
antiha
respons
respons
substanti
improv
addit
pika
vaccin
p
interestingli
titer
sera
attain
two
dose
administ
compar
titer
achiev
two
dose
given
sc
inject
p
order
demonstr
enhanc
antibodi
respons
lead
improv
efficaci
vaccin
mice
challeng
pfu
pulmonari
viral
titer
determin
day
challeng
shown
fig
mice
given
two
dose
vaccin
show
reduct
viral
titer
compar
pb
control
group
p
although
cfa
group
highest
titer
antiha
respons
fig
group
show
reduct
viral
titer
statist
differ
group
receiv
unadjuv
vaccin
p
hand
group
given
vaccin
pika
pulmonari
viral
titer
determin
previous
describ
percent
reduct
mean
viral
titer
rel
group
treat
pb
shown
column
data
symbol
indic
differ
two
group
statist
signific
p
show
potent
viral
reduct
reduct
viral
titer
compar
pb
control
group
differ
statist
signific
p
group
receiv
pika
alon
serv
control
ensur
observ
reduct
pulmonari
viral
titer
due
antiha
antibodi
respons
instead
direct
inhibitori
effect
pika
viral
replic
shown
fig
enhanc
viral
clearanc
also
observ
group
receiv
vaccin
rout
fig
mice
receiv
either
vaccin
alon
vaccin
pika
show
reduct
respect
differ
group
statist
signific
p
interest
note
although
group
receiv
vaccin
admix
cfa
highest
antibodi
titer
fig
howev
mice
higher
pulmonari
viral
titer
compar
mice
receiv
vaccin
administr
pika
fig
investig
discord
two
paramet
rel
avid
antibodi
two
group
vaccin
antigen
examin
ureadisplac
elisa
shown
fig
group
receiv
vaccin
pika
antibodi
higher
avid
surfac
glycoprotein
viru
significantli
antibodi
remain
bound
ha
expos
urea
compar
induc
cfa
adjuv
p
accumul
bodi
data
show
viru
vaccin
gener
poorli
immunogen
therefor
proceed
examin
whether
pika
effect
adjuv
vaccin
group
five
mice
inocul
sc
rout
formalininactiv
vaccin
without
adjuv
week
later
sera
collect
determin
antibodi
titer
viru
shown
fig
wholevirion
vaccin
capabl
induc
measur
titer
antibodi
one
dose
howev
inclus
pika
increas
antibodi
titer
p
compar
titer
achiev
group
receiv
vaccin
cfa
challeng
homolog
viru
howev
group
mice
group
show
signific
reduct
pulmonari
titer
day
pi
fig
p
efficaci
boost
second
dose
vaccin
pika
mice
group
show
reduct
viral
titer
fig
addit
vaccinepika
formul
efficaci
reduc
viral
replic
even
vaccin
deliv
intranas
contrast
absenc
pika
vaccin
administ
rout
fail
induc
signific
reduct
viral
titer
compar
pb
control
p
summari
demonstr
inclus
pika
two
differ
format
influenza
vaccin
achiev
substanti
antigenspar
robust
humor
immun
respons
lead
potent
pulmonari
viral
titer
reduct
vivo
attempt
elucid
biolog
basi
inhibit
viral
replic
adjuv
effect
pika
sought
identifi
receptor
might
involv
process
examin
cell
innat
immun
system
respond
pika
stimul
use
human
plasmid
show
pika
capabl
interact
specif
dosedepend
manner
fig
similar
result
obtain
experi
carri
plasmid
data
shown
next
investig
outcom
stimul
dc
vitro
pika
given
dc
potent
antigen
present
cell
apc
respons
antigen
captur
present
lymphocyt
use
primari
immatur
dc
cultur
cell
examin
dc
respond
pika
stimul
vitro
pika
ad
dc
cultur
h
follow
total
rna
extract
cell
express
level
immunolog
relat
gene
pikastimul
unstimul
sampl
compar
use
microarray
technolog
shown
fig
pikastimul
dc
upregul
express
number
cellular
activ
marker
compar
unstimul
cell
number
gene
import
immunolog
function
also
found
upregul
pika
treatment
includ
interferon
regulatori
factor
receptor
mani
chemokin
mip
macrophag
inflammatori
protein
rant
macrophag
chemoattract
protein
interferon
gamma
induc
protein
also
found
increas
express
quantit
realtim
pcr
use
confirm
find
use
cdna
unstimul
dc
baselin
mani
gene
upregul
dosedepend
manner
fig
certain
gene
ino
upregul
compar
level
lpsstimul
dc
gene
upregul
readili
pika
stimul
demonstr
observ
chang
gene
express
lead
chang
cytokineschemokin
level
protein
cultur
supernat
measur
consist
upregul
cytokinechemokin
gene
increas
product
cytokineschemokin
supernat
pikastimul
dc
compar
unstimul
dc
fig
year
sinc
first
case
human
infect
highli
pathogen
viru
identifi
hong
kong
viru
spread
mani
region
includ
southeast
asia
western
china
africa
turkey
siberia
human
case
date
involv
close
contact
infect
poultri
humantohuman
transmiss
remain
limit
nonetheless
lack
immun
human
togeth
continu
evolut
viru
close
proxim
human
popul
threaten
pandem
viru
acquir
properti
effici
transmiss
human
combin
high
casefat
rate
result
infect
viru
potenti
caus
influenza
pandem
damag
scale
similar
achiev
spanish
flu
pandem
therefor
urgent
need
develop
effect
prophylaxi
therapeut
strategi
prepar
possibl
pandem
current
studi
use
murin
influenza
model
evalu
potenti
pika
prophylaxi
treatment
influenza
infect
well
adjuv
influenza
vaccin
data
demonstr
administr
pika
intranas
prior
shortli
influenza
infect
inhibit
influenza
replic
lead
signific
reduct
pulmonari
viral
titer
effect
unlik
due
direct
antivir
activ
preincub
influenza
viru
pika
inhibit
viru
infect
embryon
chicken
egg
lynn
tang
unpublish
data
instead
pika
appear
act
stimul
innat
immun
system
fig
result
product
sever
chemokin
cytokin
interferon
turn
mediat
observ
antivir
activ
myxoviru
resist
mx
protein
protein
kinas
r
oligoadenyl
synthetas
product
report
upregul
type
interferon
product
review
ref
achiev
antivir
state
host
fact
pika
administr
result
stimul
sever
antivir
protein
host
decreas
likelihood
virus
develop
resist
mutat
furthermor
pika
target
specif
compon
virion
antivir
activ
like
effect
multipl
strain
subtyp
influenza
virus
demonstr
studi
broadspectrum
activ
limit
influenza
virus
number
studi
shown
tlrligand
capabl
inhibit
wide
rang
virus
includ
herp
simplex
cytomegaloviru
parainfluenza
west
nile
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
viru
abovement
advantag
make
novel
antivir
approach
compel
altern
tradit
antivir
drug
vaccin
especi
sinc
avian
influenza
virus
rapidli
develop
resist
antivir
drug
mutant
virus
maintain
drugresist
without
lose
virul
addit
thitithanyanont
et
al
show
stimul
dc
poli
c
confer
cell
resist
cytopath
effect
viru
might
import
induct
virusspecif
immun
respons
infect
apart
effect
agent
prophylaxi
treatment
pika
also
act
effect
adjuv
use
two
differ
form
influenza
vaccin
split
subunit
vaccin
whole
inactiv
vaccin
magnitud
humor
respons
elicit
combin
pika
compar
formul
freund
adjuv
observ
consist
report
shen
et
al
show
administ
fig
pika
induc
matur
dendrit
cell
express
wide
rang
immunolog
gene
immatur
murin
dendrit
cell
cell
incub
g
per
ml
pika
unstimul
overnight
total
rna
harvest
cell
convert
cdna
cdna
deriv
pikastimul
dc
unstimul
dc
amplifi
label
dye
respect
sampl
hybrid
overnight
microarray
chip
fluoresc
signal
measur
array
scanner
gene
target
print
time
array
normal
mean
ratio
coeffici
variat
cv
four
replic
determin
softwar
b
rna
harvest
dc
convert
cdna
express
level
cytokin
gene
determin
quantit
realtim
pcr
express
level
normal
betaactin
housekeep
gene
data
express
rel
unstimul
sampl
bar
error
bar
repres
mean
standard
deviat
triplic
sampl
repres
two
independ
experi
c
supernat
harvest
dc
stimul
overnight
either
g
pika
g
lp
unstimul
fifti
microlit
supernat
use
test
presenc
variou
cytokineschemokin
supernat
use
bioplex
protein
array
system
measur
duplic
bar
error
bar
repres
mean
standard
error
pika
hepat
b
vaccin
boost
humor
respons
explor
concept
demonstr
substanti
antigenspar
effect
could
achiev
incorpor
pika
vaccin
use
commerci
split
vaccin
antigenspar
effect
fig
b
furthermor
demonstr
augment
humor
respons
led
function
reduct
viral
titer
fig
data
also
show
success
immun
could
achiev
nonparenter
rout
two
dose
magnitud
respons
achiev
intranas
immun
compar
achiev
subcutan
immun
associ
similar
level
viral
clearanc
find
consist
report
ichinoh
et
al
show
anoth
ligand
ampligen
capabl
enhanc
immunogen
trival
inactiv
influenza
vaccin
administr
intranas
studi
enhanc
effect
demonstr
use
higher
dose
trival
vaccin
g
current
studi
extend
observ
show
similar
enhanc
effect
achiev
even
concentr
immunogen
reduc
g
lower
antigenspar
effect
pika
might
import
strategi
maxim
vaccin
coverag
vaccin
suppli
limit
interest
note
although
group
receiv
influenza
vaccin
pika
highest
antibodi
titer
lowest
pulmonari
viral
titer
reduct
compar
cfa
adjuv
vaccin
group
higher
avid
antibodi
induc
vaccin
pika
might
allow
effect
inhibit
viral
replic
vivo
translat
lower
pulmonari
viral
titer
observ
studi
suggest
addit
augment
amount
antibodi
produc
pika
may
also
impact
qualiti
humor
respons
affin
matur
pika
stabil
form
doubl
strand
ds
rna
lack
direct
antiinfluenza
activ
evalu
effect
innat
immun
system
search
mechan
underli
observ
activ
dsrna
shown
ligand
use
transient
transfect
system
show
pika
maintain
bind
properti
incub
pika
primari
immatur
murin
dc
vitro
result
matur
dendrit
cell
mark
upregul
costimulatori
molecul
cytokin
potent
immunostimulatori
function
observ
consist
observ
shen
et
al
bmdc
matur
process
enabl
dc
act
potent
antigen
present
cell
effect
activ
lymphocyt
turn
lead
robust
immun
respons
addit
studi
conduct
perera
et
al
show
vaccinia
viru
express
induc
superior
cellular
humor
immun
respons
compar
parent
strain
therefor
induct
pika
could
also
result
effici
induct
cell
respons
translat
robust
humor
respons
lung
tissu
recent
shown
constitut
express
vivo
mice
intranas
administr
pika
could
directli
stimul
express
cell
perhap
pika
work
effect
administr
intranas
fig
believ
pika
similar
antivir
activ
human
show
human
recogn
pika
fig
number
studi
demonstr
express
variou
respiratori
cell
type
nasal
epitheli
cell
airway
smooth
muscl
cell
airway
epitheli
cell
addit
ds
rna
found
effect
tlr
ligand
activ
airway
epitheli
cell
produc
although
experiment
data
limit
dsrna
also
recogn
rna
helicas
induc
nfb
activ
ifn
possibl
pika
stimul
sever
pathway
vivo
achiev
antivir
adjuv
activ
knockoutmic
ko
ko
ko
mice
use
shed
light
contribut
receptor
activ
pika
summari
although
poli
c
shown
effect
mucos
adjuv
use
clinic
trial
associ
sideeffect
limit
usag
recent
toxic
trial
pika
show
signific
toxic
mice
phase
clinic
studi
show
use
pika
adjuv
welltoler
human
without
signific
sideeffect
peter
brazier
unpublish
data
safeti
profil
togeth
long
shelflif
make
pika
attract
complement
current
licens
antivir
drug
earli
phase
influenza
pandem
wellmatch
vaccin
unlik
avail
pika
use
antivir
drug
temporari
protect
suscept
popul
slow
rate
viral
transmiss
allow
time
vaccin
product
furthermor
global
influenza
vaccin
product
like
lag
well
behind
demand
pandem
influenza
vaccin
inclus
effect
antigenspar
adjuv
pika
ensur
limit
suppli
vaccin
achiev
maximum
coverag
